---
created: 2025-04-13
updated: 2025-04-13T10:51
id: Nb5C|<{MVk
specialty: cardio
specialty_id: 185
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::03-biochem::05-lipids::03-lipid-drugs
  - source/ak-step1-v11::
  - theme/firstaid::05-pharmacology::03-toxicities-&-side-effects::06-drug-reactions---msk/skin/connect-tissue
  - source/ak-step1-v11::
  - theme/firstaid::07-cardiovascular::05-pharm::10-lipid-lowering-agents::statins
  - source/ak-step1-v11::
  - theme/nbme::20
  - source/ak-step1-v11::
  - theme/nbme::21
  - source/ak-step1-v11::
  - source/ome-banner::clinical::01-cardiology::07-cholesterol
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::10-cardiac::09-statins
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::10-cardiac::12-fibrates
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::06-cardio::hmg-coa-reductase-inhibitors-(statins)
  - source/ak-step1-v11::
  - theme/sketchypharm::03-blood-&-inflammation::02-dyslipidemia-drugs::01-statins
  - source/ak-step1-v11::
  - theme/uworld::100-999::700-799::712
  - source/ak-step1-v11::
  - theme/uworld::100-999::700-799::778
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - source/ak-step2-v11::!shelf::fm
  - source/ak-step2-v11::!shelf::fm::no-dupes
  - source/ak-step2-v11::!shelf::im
  - source/ak-step2-v11::!shelf::im::no-dupes
  - source/ak-step2-v11::
  - theme/b&b::01-cardiology::other::hyperlipidemia
  - source/ak-step2-v11::
  - theme/ome::01-cardiology::07-cholesterol
  - source/ak-step2-v11::
  - source/ome-banner::clinical::01-cardiology::07-cholesterol
  - source/ak-step2-v11::
  - theme/resources-by-rotation::fm::ome::cardio::cholesterol
  - source/ak-step2-v11::
  - theme/resources-by-rotation::im::ome::cardio::cholesterol
  - source/ak-step2-v11::
  - theme/subjects::*pharm-extra::lipid-drugs::statins
  - source/ak-step2-v11::original-decks::dorian::fam::ome::cardio::cholesterol
  - source/ak-step2-v11::original-decks::dorian::im::ome::cardio::cholesterol"
type: flashcard
---

# Question
The most common side effect of statins is **myopathy**, which occurs weeks to months after starting therapy

---

# Answer
AE = statin-induced myalgia or myopathy (eg, muscle weakness, soreness), w/w/o myonecrosis (high CK creatine kinase), to frank rhadomyolysis; Can be exacerbated by concomitant fibrate use    Statins (ie, HMG-CoA reductase inhibitors) == increased LDL receptor recycling == allows normal intrahepatic levels while keeping blood cholesterol low